Inbec的注意事项

Suimeike (Dolutea Paramid Tablets, Inbec) is a drug with very significant effect in treating AIDS (HIV). So what should patients pay attention to when taking Suimeike (Dolutea Paramid Tablets, Inbec)? Today we will take a look at the precautions for Suimeikai (Abalamid Tablets, Inbec).

1. Transmission of HIV: Although it has been proven that suppressing the virus with antiretroviral treatment can significantly reduce the risk of sexual transmission, residual risks cannot be ruled out. Precautions should be taken to prevent transmission in accordance with national guidance. 

2. Weight and metabolic parameters (lipid and glucose): During antiretroviral treatment, weight gain and elevated lipid and glucose levels may occur. These changes may be related in part to disease control and lifestyle. In some cases, there is evidence of an effect of treatment on lipids, but there is no clear evidence that weight gain is associated with any specific treatment. Monitoring of lipids and glucose should refer to established HIV treatment guidelines. Dyslipidemias should be treated appropriately based on the clinical situation.

3. Liver disease: The safety and effectiveness of Suimeikan have not been established in patients with pre-existing severe liver disease. Suimeikan is not recommended for patients with moderate to severe liver damage. Patients with pre-existing hepatic dysfunction, including those with chronic active hepatitis, develop hepatic dysfunction with increased frequency during combined antiretroviral therapy and should be monitored according to standard protocols. If in these patients there is evidence of worsening liver disease, withholding or discontinuing treatment should be considered. 

4. Osteonecrosis: Although the etiology is thought to be multifactorial (including use of corticosteroids, bisphosphonates, alcohol consumption, severe immunosuppression, and high body mass index), cases of osteonecrosis have been reported, particularly in patients with advanced HIV disease and/or long-term exposure to CART. Patients should be advised to seek medical attention if they experience joint pain, joint stiffness, or difficulty moving. 

5. Opportunistic infections: Patients should be informed that HIV infection cannot be cured by Trimax or any other antiretroviral treatment, and they may still develop opportunistic infections and other complications of HIV infection. Therefore, patients should be under close clinical observation by physicians experienced in treating HIV-related diseases. 

6. Patients with chronic hepatitis B or hepatitis C: Patients with chronic hepatitis B or hepatitis C who receive combination therapy with antiretroviral drugs are at increased risk of severe and potentially fatal liver adverse reactions. If you are also taking antiviral treatment for hepatitis B or hepatitis C, please refer to the relevant product information for these medicines.

The above are the precautions for Suimeikai (Domitabalamid Tablets, Inbec) provided by our Medical Companion Travel. Patients must read it carefully and use it rationally.